Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy

Thromb Res. 2022 Feb:210:87-90. doi: 10.1016/j.thromres.2021.12.028. Epub 2022 Jan 4.

¹ Sysmex Corporation, Kobe, Hyogo, Japan.
² Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.
³ Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
⁴ Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
⁵ Department of Cerebrovascular Medicine and Neurology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
⁶ Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan; Department of Clinical Laboratory, Iwate Prefectural Chubu Hospital, Iwate, Japan. Electronic address: iekomNo2020@gmail.com.

No abstract available

Keywords: Apixaban; Edoxaban; Oral anticoagulant; Prothrombin time; Rivaroxaban.

Publication types